CYTH Company Profile and Key Details

Q: Who are the executives of CYTH?

Mr. C. E StrattanFounder & DirectorMs. Lori McKenna GorskiGlobal Head of Patient AdvocacyDr. Karen Mullen FFPMInterim Chief Medical OfficerDr. Jeffrey L. Tate Ph.D.Chief Operating Officer, Chief Quality Officer & DirectorMr. Michael Eric LisjakChief Regulatory Officer & Senior Vice President of Bus. Devel.Mr. N. Scott FineChief Executive Officer & DirectorMr. Joshua M. FineChief Financial Officer & Sec.Mr. George L. FailsExecutive Vice President and Operations Mang.Dr. Lise Lund Kjems M.D., Ph.D.Chief Medical Officer

NASDAQ : CYTH

Cyclo Therapeutics

$0.72

Open: 4:00 PM

Not Actively Trading

68.56

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cyclo Therapeutics, Inc. (CYTH) stock remained unchanged at $0.72 a share on NASDAQ. The stock opened at $0.72, fluctuating between $0.72 to $0.72 during the session.

Stock Snapshot

0.7206

Prev. Close

23.59M

Market Cap

0.7206

Day Low

-0.8006666666666666

P/E Ratio

-0.9

EPS (TTM)

-0.65

Cash Flow per Share

0.72

Open

32.74M

Number of Shares

0.7206

Day High

35.17%

Free Float in %

0.19

Book Value

186.81K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 27, 2025	0.72	0.72	0.72	0.72	0
Mar 26, 2025	0.72	0.72	0.72	0.72	0
Mar 25, 2025	0.66	0.73	0.63	0.72	188.27K
Mar 24, 2025	0.69	0.73	0.65	0.71	40.3K
Mar 21, 2025	0.69	0.70	0.65	0.70	35.3K
Mar 20, 2025	0.64	0.69	0.62	0.68	26.67K
Mar 19, 2025	0.64	0.68	0.64	0.67	38.52K
Mar 18, 2025	0.64	0.67	0.62	0.65	64.85K
Mar 17, 2025	0.70	0.73	0.64	0.66	78.8K
Mar 14, 2025	0.76	0.76	0.69	0.70	33.64K
Mar 13, 2025	0.66	0.73	0.66	0.70	28.04K
Mar 12, 2025	0.71	0.72	0.67	0.67	29.42K
Mar 11, 2025	0.70	0.75	0.68	0.68	19.61K
Mar 10, 2025	0.73	0.76	0.70	0.70	65.61K
Mar 07, 2025	0.76	0.79	0.73	0.74	16K
Mar 06, 2025	0.71	0.79	0.71	0.75	135.87K
Mar 05, 2025	0.71	0.76	0.70	0.71	32.09K
Mar 04, 2025	0.73	0.73	0.70	0.71	43.2K
Mar 03, 2025	0.74	0.80	0.70	0.75	194.3K
Feb 28, 2025	0.75	0.77	0.73	0.76	46.81K

Contact Details

Gainesville, FL 32653

United States

https://www.cyclotherapeutics.com 386 418 8060

About Company

Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.

Stock Peers

ITCI

Intra-Cellular Therapies, Inc.$131.87 LNTH

3.55+3.40%

Lantheus Holdings, Inc.$107.95 ANIP

1.43+1.84%

ANI Pharmaceuticals, Inc.$79.15 SUPN

0.45+0.95%

Supernus Pharmaceuticals, Inc.$47.87 HROW

-0.74-1.66%

Harrow Health, Inc.$43.71 ETON

2.13+5.19%

Eton Pharmaceuticals, Inc.$43.20 INDV

1.33+3.40%

Indivior Pharmaceuticals Inc$40.45 COLL

0.31+0.87%

Collegium Pharmaceutical, Inc.$35.85 PAHC

0.81+2.45%

Phibro Animal Health Corporation$33.86 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98

Company Overview

The stock is currently mid-range between its 52-week high and low $0.55 and $1.62. With a market capitalization of about $23.59 million, Cyclo Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.57). Key stats such as the average daily volume over the past year has been around 1.76 million shares, volume is running light vs its 52-week average. Headquartered in Gainesville, FL, Cyclo Therapeutics, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO N. Scott Fine, the company employs approximately 8 people and listed since May 03, 2000. Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions.

Technical Performance

CYTH has shown sold momentum, gaining 5.97% over the past week and 19.7% over the past quarter, though year-to-date performance is up 22.14%. Short-term trend indicators are bullishly aligned (SMA20 1.45%, SMA50 -8.57%, SMA200 -15.88%). The stock’s 14-day RSI is 47.9 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.74% below its high and over 31.02% above its low.

Valuation Metrics

Cyclo Therapeutics, Inc. trades at a P/E ratio of -0.59, slightly below the S&P 500 average, with a price-to-sales ratio of 21.92 and a price-to-book ratio of 2.47 suggesting the stock is closer to book value. The P/FCF stands at -1.46, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Cyclo Therapeutics, Inc. generated EPS of -$0.90 over the past year. Five-year average earnings growth is -88.22%. The latest quarter delivered EPS of -$0.26. The next quarter is forecast at $nan. Next year's EPS is expected at $38.39. Cyclo Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2024, missed forecasts by 52.94%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include 9.52% in May 15, 2023.

Shareholding & Insider Activity

Cyclo Therapeutics, Inc. has 32.74 million shares outstanding. The public float is 11.51 million shares, elevated short interest at 1.51% of float. This equals 434.12 thousand shares. The short ratio is 5.58 days. Institutional investors hold 22.21% of the float. Insiders own 48.45%. ARMISTICE CAPITAL, LLC holds 15.80 million shares, Rafael Holdings, Inc. has 2.77 million shares and FINE N SCOTT has 329.34 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Cyclo Therapeutics generated $1.08M in revenue, or $0.07 per share. Gross margin was -223.91%, operating margin -1862.69%, and net profit margin -1863.36%. Returns are negative, with ROA at -151.40% and ROE at -421.64%.
On valuation metrics, Cyclo Therapeutics trades at a P/E of -0.59, P/S of 21.92 and P/B of 2.47. The current ratio is 1.45 and quick ratio is 1.42. Operationally, the company’s inventory turnover is 0.39 and cash conversion cycle is -17019.53 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.22, supported by a cash flow-to-debt ratio of -15.67.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Cyclo Therapeutics posted revenue of $1.08M, down slightly from $1.38M in the prior quarter. Gross profit was - $2.41M (margin -223.91%). Operating income was - $20.05M (margin -1862.7%). Net income was- $20.06M (EPS - $1.23).
The company ended the quarter with $9.25M in cash and short-term investments, a total debt of $1.03M, and net debt of - $8.21M. Total assets were $13.25M, with equity of $4.76M. Financials further reflected weakness, with operating cash flow of - $16.19M, free cash flow of - $16.19M, and capital expenditures of - $2.42K.

Price Forecast & Outlook

Our AI price prediction model suggests that Cyclo Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.06%, with price expected at $0.54 by April 10, 2025, within a range of $0.45 to $0.63 3-Month Outlook: Projected fall of -32.0%, reaching $0.49 by June 25, 2025, with a range of $0.43 to $0.54. 1-Year Outlook: Projected gain of 51.26%, with price at $1.09 by March 27, 2026, within a range of $0.00 to $0.33.

Key Takeaways

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) shares are up 22.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cyclo Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.59. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $2.38, suggesting 230.28% upside. Our AI forecast model points to short-term weakness (-25.06% over two weeks), a medium-term fall (-32.0% over three months), and a longer-term gain (51.26% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Cyclo Therapeutics, Inc. (CYTH) stock price?

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) stock price is $0.72 in the last trading session. During the trading session, CYTH stock reached the peak price of $0.72 while $0.72 was the lowest point it dropped to. The percentage change in CYTH stock occurred in the recent session was 0% while the dollar amount for the price change in CYTH stock was $0.00.

CYTH's industry and sector of operation?

The NASDAQ listed CYTH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Cyclo Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CYTH?

Mr. C. E Strattan
Founder & Director
Ms. Lori McKenna Gorski
Global Head of Patient Advocacy
Dr. Karen Mullen FFPM
Interim Chief Medical Officer
Dr. Jeffrey L. Tate Ph.D.
Chief Operating Officer, Chief Quality Officer & Director
Mr. Michael Eric Lisjak
Chief Regulatory Officer & Senior Vice President of Bus. Devel.
Mr. N. Scott Fine
Chief Executive Officer & Director
Mr. Joshua M. Fine
Chief Financial Officer & Sec.
Mr. George L. Fails
Executive Vice President and Operations Mang.
Dr. Lise Lund Kjems M.D., Ph.D.
Chief Medical Officer

How CYTH did perform over past 52-week?

CYTH's closing price is 31.02% higher than its 52-week low of $0.55 where as its distance from 52-week high of $1.62 is -55.52%.

How many employees does CYTH have?

Number of CYTH employees currently stands at 8.

Link for CYTH official website?

Official Website of CYTH is: https://www.cyclotherapeutics.com

How do I contact CYTH?

CYTH could be contacted at phone 386 418 8060 and can also be accessed through its website. CYTH operates from 6714 NW 16th Street, Gainesville, FL 32653, United States.

How many shares of CYTH are traded daily?

CYTH stock volume for the day was 186.81K shares. The average number of CYTH shares traded daily for last 3 months was 1.76M.

What is the market cap of CYTH currently?

The market value of CYTH currently stands at $23.59M with its latest stock price at $0.72 and 32.74M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	8
Beta	-0.57
Sales or Revenue	$1.08M
5Y Sales Change%	-0.947%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

CYTH Company Profile and Key Details

Cyclo Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Company Overview

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways